Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct;106(4):726-733.
doi: 10.1002/cpt.1477. Epub 2019 Jul 5.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy

Affiliations
Free PMC article

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy

Zeruesenay Desta et al. Clin Pharmacol Ther. .
Free PMC article

Abstract

The HIV type-1 nonnucleoside reverse transcriptase inhibitor, efavirenz, is widely used to treat HIV type-1 infection. Efavirenz is predominantly metabolized into inactive metabolites by cytochrome P450 (CYP)2B6, and patients with certain CYP2B6 genetic variants may be at increased risk for adverse effects, particularly central nervous system toxicity and treatment discontinuation. We summarize the evidence from the literature and provide therapeutic recommendations for efavirenz prescribing based on CYP2B6 genotypes.

Conflict of interest statement

Conflicts of Interest:

As an Associate Editor for Clinical Pharmacology & Therapeutics, Rachel Tyndale was not involved in the review or decision process for this paper. All other authors declared no competing interests for this work.

Similar articles

See all similar articles

Cited by 7 articles

See all "Cited by" articles

Publication types

LinkOut - more resources

Feedback